Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 23, 2026, 2:21 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Essential Thrombocythemia (ET) Clear all
Completed No phase listed Observational Accepts healthy volunteers

Polycythemia Vera, Myelofibrosis and Essential Thrombocythemia: Identification of PV, MF & ET Genes

NCT00715247
View directory record Official record
Conditions
Polycythemia Vera, Essential Thrombocythemia, Myelofibrosis
Interventions
Not listed
Lead sponsor
University of Utah
Other
Eligibility
Not listed
Enrollment
726 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2018
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Oct 14, 2019 · Synced Jul 23, 2026, 2:21 PM EDT
Active, not recruiting Phase 3 Interventional

Bomedemstat vs Hydroxyurea for Essential Thrombocythemia (MK-3543-007)

NCT06456346
View directory record Official record
Conditions
Essential Thrombocythemia
Interventions
Bomedemstat, Hydroxyurea, Bomedemstat placebo, Hydroxyurea placebo
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
22
States / cities
Glendale, Arizona • Glendale, California • Palo Alto, California + 19 more
Source: ClinicalTrials.gov public record
Updated Jul 16, 2026 · Synced Jul 23, 2026, 2:21 PM EDT
Completed Phase 2 Interventional Results available

Clinical Trial of Aplidin® in Patients With Primary Myelofibrosis

NCT01149681
View directory record Official record
Conditions
Myelofibrosis
Interventions
APLIDIN (plitidepsin)
Drug
Lead sponsor
PharmaMar
Industry
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Oct 11, 2020 · Synced Jul 23, 2026, 2:21 PM EDT
Terminated Phase 1 Interventional

A Study of TAS1553 in Subjects With Relapsed or Refractory Acute Myeloid Leukemia (AML) and Other Myeloid Neoplasms

NCT04637009
View directory record Official record
Conditions
Acute Myeloid Leukemia, Myeloproliferative Neoplasm, Myelodysplastic/Myeloproliferative Neoplasm
Interventions
TAS1553
Drug
Lead sponsor
Astex Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
8
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Los Angeles, California + 5 more
Source: ClinicalTrials.gov public record
Updated Aug 1, 2024 · Synced Jul 23, 2026, 2:21 PM EDT
Completed Phase 2 Interventional Results available

To Assess the Safety, Tolerability and Efficacy of Itacitinib Immediate Release Tablets in Participants With Primary or Secondary Myelofibrosis Who Have Received Prior Ruxolitinib and/or Fedratinib Monotherapy (LIMBER-213)

NCT04629508
View directory record Official record
Conditions
Myelofibrosis, Polycythemia Vera, Thrombocythemia
Interventions
itacitinib
Drug
Lead sponsor
Incyte Corporation
Industry
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
8
States / cities
New Orleans, Louisiana • Bethesda, Maryland • Kansas City, Missouri + 5 more
Source: ClinicalTrials.gov public record
Updated Sep 1, 2025 · Synced Jul 23, 2026, 2:21 PM EDT
Active, not recruiting Phase 2 Interventional

Extended Access of Momelotinib in Adults With Myelofibrosis

NCT03441113
View directory record Official record
Conditions
Neoplasms, Post-polycythemia Vera Myelofibrosis (Post-PV MF), Primary Myelofibrosis (PMF), Post-essential Thrombocythemia Myelofibrosis (Post-ET MF), Primary Myelofibrosis
Interventions
MMB
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
237 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2026
U.S. locations
14
States / cities
Scottsdale, Arizona • Orange, California • Stanford, California + 11 more
Source: ClinicalTrials.gov public record
Updated Jun 17, 2026 · Synced Jul 23, 2026, 2:21 PM EDT
Completed Phase 2 Interventional Results available

Momelotinib in Transfusion-Dependent Adults With Primary Myelofibrosis (PMF) or Post-polycythemia Vera or Post-essential Thrombocythemia Myelofibrosis (Post-PV/ET MF)

NCT02515630
View directory record Official record
Conditions
Primary Myelofibrosis (PMF), Post-polycythemia Vera (Post-PV) Myelofibrosis, Postessential Thrombocythemia (Post-ET) Myelofibrosis
Interventions
MMB
Drug
Lead sponsor
Sierra Oncology LLC - a GSK company
Industry
Eligibility
18 Years and older
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
12
States / cities
Phoenix, Arizona • Los Angeles, California • Orange, California + 9 more
Source: ClinicalTrials.gov public record
Updated Jun 17, 2023 · Synced Jul 23, 2026, 2:21 PM EDT
Active, not recruiting Phase 2 Interventional

IMG-7289 in Patients With Essential Thrombocythemia (ET) or Polycythemia Vera (PV)

NCT04262141
View directory record Official record
Conditions
Essential Thrombocythemia, Polycythemia Vera
Interventions
IMG-7289
Drug
Lead sponsor
Terrence J Bradley, MD
Other
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Jan 6, 2026 · Synced Jul 23, 2026, 2:21 PM EDT
Completed Phase 2 Interventional Results available

LCL161 in Treating Patients With Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocytosis Myelofibrosis

NCT02098161
View directory record Official record
Conditions
Polycythemia Vera, Post-Polycythemic Myelofibrosis Phase, Primary Myelofibrosis, Secondary Myelofibrosis
Interventions
Laboratory Biomarker Analysis, Questionnaire Administration, Smac Mimetic LCL161
Other · Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2022
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 5, 2023 · Synced Jul 23, 2026, 2:21 PM EDT
Active, not recruiting Phase 2 Interventional

Study of Canakinumab in Patients With Myelofibrosis

NCT05467800
View directory record Official record
Conditions
Primary Myelofibrosis, Post-essential Thrombocythemia Myelofibrosis, ET-MF, Post-polycythemia Vera Related Myelofibrosis, PV-MF
Interventions
Canakinumab
Drug
Lead sponsor
John Mascarenhas
Other
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
7
States / cities
Los Angeles, California • Tampa, Florida • Westwood, Kansas + 4 more
Source: ClinicalTrials.gov public record
Updated May 6, 2026 · Synced Jul 23, 2026, 2:21 PM EDT
Terminated Phase 1 Interventional

Assess the Safety, Tolerability Oral PU-H71 in Subjects Taking Ruxolitinib

NCT03935555
View directory record Official record
Conditions
Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (Post-PV MF), Post-Essential Thrombocythemia Myelofibrosis (Post-ET MF)
Interventions
PU-H71
Drug
Lead sponsor
Samus Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
3
States / cities
Larkspur, California • Los Angeles, California • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Nov 16, 2022 · Synced Jul 23, 2026, 2:21 PM EDT
Completed Phase 3 Interventional Results available

Randomized Trial of Pegylated Interferon Alfa-2a Versus Hydroxyurea in Polycythemia Vera (PV) and Essential Thrombocythemia (ET)

NCT01259856
View directory record Official record
Conditions
High Risk Polycythemia Vera, High Risk Essential Thrombocythemia
Interventions
PEGASYS, Hydroxyurea, Aspirin
Drug
Lead sponsor
Ronald Hoffman
Other
Eligibility
18 Years and older
Enrollment
168 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2017
U.S. locations
16
States / cities
Scottsdale, Arizona • Los Angeles, California • Palo Alto, California + 10 more
Source: ClinicalTrials.gov public record
Updated Apr 29, 2019 · Synced Jul 23, 2026, 2:21 PM EDT
Completed Phase 3 Interventional Results available

A Study of Momelotinib Versus Danazol in Symptomatic and Anemic Myelofibrosis Participants (MOMENTUM)

NCT04173494
View directory record Official record
Conditions
Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis, Post-essential Thrombocythemia Myelofibrosis
Interventions
Momelotinib, Placebo to match danazol, Danazol, Placebo to match momelotinib
Drug
Lead sponsor
Sierra Oncology LLC - a GSK company
Industry
Eligibility
18 Years and older
Enrollment
195 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
17
States / cities
Phoenix, Arizona • Irvine, California • Los Angeles, California + 14 more
Source: ClinicalTrials.gov public record
Updated Oct 31, 2023 · Synced Jul 23, 2026, 2:21 PM EDT
Active, not recruiting Phase 3 Interventional

Ropeginterferon Alfa-2b (P1101) vs. Anagrelide in Essential Thrombocythemia Patients With Hydroxyurea Resistance or Intolerance

NCT04285086
View directory record Official record
Conditions
Essential Thrombocythemia
Interventions
Ropeginterferon alfa-2b, Anagrelide
Biological · Drug
Lead sponsor
PharmaEssentia
Industry
Eligibility
18 Years and older
Enrollment
174 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2029
U.S. locations
4
States / cities
Scottsdale, Arizona • St Louis, Missouri • Houston, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 21, 2026 · Synced Jul 23, 2026, 2:21 PM EDT
Active, not recruiting Phase 1 Interventional

Safety and Tolerability Study of INCB057643 in Participants With Myelofibrosis and Other Advanced Myeloid Neoplasms

NCT04279847
View directory record Official record
Conditions
Myelofibrosis, Myelodysplastic Syndrome, Myelodysplastic/Myeloproliferative Neoplasm Overlap Syndrome, Myeloproliferative Neoplasm, Relapsed or Refractory Primary Myelofibrosis, Secondary Myelofibrosis (Post-Polycythemia Vera Myelofibrosis, Post-Essential Thrombocythemia Myelofibrosis), ET (Essential Thrombocythemia)
Interventions
INCB057643, Ruxolitinib
Drug
Lead sponsor
Incyte Corporation
Industry
Eligibility
18 Years and older
Enrollment
140 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
19
States / cities
Birmingham, Alabama • Aurora, Colorado • Miami, Florida + 14 more
Source: ClinicalTrials.gov public record
Updated Mar 31, 2026 · Synced Jul 23, 2026, 2:21 PM EDT
Completed Phase 2 Interventional Results available

Pomalidomide for Myelofibrosis Patients

NCT00946270
View directory record Official record
Conditions
Polycythemia Vera, Thrombocythemia
Interventions
CC-4047, Prednisone
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2018
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 9, 2019 · Synced Jul 23, 2026, 2:21 PM EDT
Not listed Phase 2 Interventional

Study of KRT-232 or TL-895 in Janus Associated Kinase Inhibitor Treatment-Naïve Myelofibrosis

NCT04878003
View directory record Official record
Conditions
Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (Post-PV-MF), Post-Essential Thrombocythemia Myelofibrosis (Post-ET-MF)
Interventions
KRT-232, TL-895
Drug
Lead sponsor
Kartos Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
4
States / cities
Glendale, California • Whittier, California • Canton, Ohio + 1 more
Source: ClinicalTrials.gov public record
Updated May 8, 2022 · Synced Jul 23, 2026, 2:21 PM EDT
Completed Phase 2 Interventional Results available

Ruxolitinib Phosphate and Danazol in Treating Anemia in Patients With Myelofibrosis

NCT01732445
View directory record Official record
Conditions
Anemia, Primary Myelofibrosis, Secondary Myelofibrosis
Interventions
ruxolitinib phosphate, danazol, quality-of-life assessment, questionnaire administration
Drug · Other
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
2
States / cities
Scottsdale, Arizona • New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 17, 2017 · Synced Jul 23, 2026, 2:21 PM EDT
Active, not recruiting Phase 2 Interventional

A Single-arm, Multicenter Study to Assess the Efficacy, Safety, and Tolerability of P1101 in Adults With ET

NCT05482971
View directory record Official record
Conditions
Essential Thrombocythemia
Interventions
Ropeginterferon alfa-2b-njft (P1101)
Drug
Lead sponsor
PharmaEssentia
Industry
Eligibility
18 Years and older
Enrollment
91 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
30
States / cities
Birmingham, Alabama • Duarte, California • Greenbrae, California + 25 more
Source: ClinicalTrials.gov public record
Updated Aug 12, 2025 · Synced Jul 23, 2026, 2:21 PM EDT
Active, not recruiting Phase 3 Interventional

A Study of Bomedemstat (IMG-7289/MK-3543) Compared to Best Available Therapy (BAT) in Participants With Essential Thrombocythemia and an Inadequate Response or Intolerance of Hydroxyurea (MK-3543-006)

NCT06079879
View directory record Official record
Conditions
Essential Thrombocythemia
Interventions
Bomedemstat, Anagrelide, Busulfan, Interferon alfa/pegylated interferon alfa 2a/pegylated interferon alfa 2b, Ruxolitinib
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
340 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
16
States / cities
Glendale, Arizona • Glendale, California • Stanford, California + 13 more
Source: ClinicalTrials.gov public record
Updated Jul 16, 2026 · Synced Jul 23, 2026, 2:21 PM EDT
Recruiting Phase 2 Interventional

MethoTRExATE in MyelOpRolifErative Neoplasms (TREATMORE) Trial

NCT06541249
View directory record Official record
Conditions
Polycythemia Vera (PV), Essential Thrombocythemia (ET), Myelofibrosis (MF)
Interventions
Methotrexate (MTX)
Drug
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years and older
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 16, 2025 · Synced Jul 23, 2026, 2:21 PM EDT
Terminated Phase 2 Interventional Results available

Single-Arm Study of the Efficacy and Safety of Oral Rigosertib in Patients With Myelofibrosis (MF) and Anemia

NCT02730884
View directory record Official record
Conditions
Leukemia, Myelofibrosis, Anemia, Splenomegaly
Interventions
Rigosertib, Questionnaire
Drug · Behavioral
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 6, 2020 · Synced Jul 23, 2026, 2:21 PM EDT
Terminated Phase 3 Interventional Results available

A Trial of Fedratinib in Subjects With DIPSS, Intermediate or High-Risk Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis and Previously Treated With Ruxolitinib

NCT03755518
View directory record Official record
Conditions
Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, Myelofibrosis, Post-essential Thrombocythemia Myelofibrosis
Interventions
FEDRATINIB
Drug
Lead sponsor
Celgene
Industry
Eligibility
18 Years and older
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
28
States / cities
Aurora, Colorado • Miami, Florida • Augusta, Georgia + 23 more
Source: ClinicalTrials.gov public record
Updated Dec 11, 2024 · Synced Jul 23, 2026, 2:21 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Safety and Tolerability Study of Oral NS-018 in Patients With Primary Myelofibrosis (MF), Post-polycythemia Vera MF or Post-essential Thrombocythemia MF

NCT01423851
View directory record Official record
Conditions
Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, Post-Essential Thrombocythemia Myelofibrosis
Interventions
NS-018
Drug
Lead sponsor
NS Pharma, Inc.
Industry
Eligibility
18 Years and older
Enrollment
77 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2020
U.S. locations
9
States / cities
Scottsdale, Arizona • San Diego, California • Jacksonville, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Mar 8, 2022 · Synced Jul 23, 2026, 2:21 PM EDT